Talphera, Inc. Overview
Pro stress-test →Talphera is a specialty pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate, Niyad, is a lyophilized formulation of nafamostat being studied as an anticoagulant for the extracorporeal circuit. The company is progressing clinical trials with potential market applications in dialysis and critical care.
Strategic Profile
Pro stress-test →The company is also developing LTX-608, a nafamostat formulation for direct IV infusion for indications including antiviral, acute respiratory distress syndrome, disseminated intravascular coagulation, and acute pancreatitis, as well as pre-filled syringe product candidates. The FDA approved reducing the NEPHRO CRRT clinical study from 166 to 70 patients with 90% power, and the company activated clinical study sites targeting completion by year-end 2025.
Competitive Landscape
Pro stress-test →Talphera competes in specialized anticoagulation and critical care therapeutics space. Competitors include larger pharma companies with established dialysis solutions and emerging biotech firms developing nafamostat formulations. The company's niche focus on medically supervised settings with specialized delivery mechanisms differentiates it, though it faces competition from established anticoagulation providers and broader ARDS/critical care treatment developers.
Industry Context
Talphera, Inc. operates in Specialty Pharmaceuticals / Biotech.
Key facts
Founded: 2005 · Headquarters: San Mateo, California · Market cap: $51.5M